The Foundation APS ONLUS was set up by a group of doctors and patients who wanted to fill a gap in the research area of immune and blood disorders and more specifically in autoimmune disorders.. continue...
The antiphospholipid syndrome (APS) is an autoimmune disease in which the immune system of the affected person does not recognise its own body and attacks some of its parts. More specifically this attack is carried out by antibodies against phospholipids (aPL) (a particular type of fat) associated with anticlotting factors present in the blood stream.
The prevalence of aPL in the general population is around 5%; in patients with systemic lupus erythematosus the prevalence ranges between 30-40% though only 10% of lupus patients ever develops thrombosis...
The prevalence of aPL detected via immune assay in people with deep vein thrombosis is around 24% whereas the prevalence of aPL detected via clotting tests is around 4%...
The prevalence of a first venous thrombosis in patients with APS varies between 41 and 58% and that of isolated pulmonary embolism is around 12%...
The prevalence of a first arterial clot varies between 26 and 36%: from 16 to 42% of patients present with an ischaemic stroke and from 7 to 37% of patients present with myocardial..
Post-translational modifications of plasma fibrinogen as a thrombotic risk factor in primary APS and systemic lupus erythematosus.
Budget required: euros 12.000
Budget available: euros 3.000 (February 2019)
Clinical relevance of antibodies against modified clotting proteins in systemic lupus erythematosus and antiphospholipid syndrome.
Budget required: euros 16.000
Budget available: euros 4.000 (February 2019)
The Fondazione Anticorpi Antifosfolipidi ONLUS promotes research on the origin and the mechanisms through which antiphospholipid antibodies induce thrombosis, atherosclerosis and miscarriages. This information are preliminary to the development of strategies to limit antibody production and minimise the risk ...continue
